Patent Landscape and Claims Analysis for US Patent 6,727,283
What is the scope of US Patent 6,727,283?
US Patent 6,727,283, filed on September 19, 2000, and granted on April 27, 2004, covers a specific class of compounds designed for therapeutic or diagnostic use. Its primary focus involves small-molecule inhibitors targeting a particular enzyme or receptor, with specific structural features delineated in its claims.
Key Elements of the Patent
- Chemical Structure: The patent claims a class of compounds characterized by a core chemical structure, typically including a specific heterocyclic ring system linked to various substituents. The claims specify optional and variable groups that define the scope of the compounds covered.
- 用途: The patent claims use for treating diseases related to the targeted enzyme or receptor, such as certain cancers or inflammatory conditions.
- Methods: It describes methods of synthesizing these compounds and their use in pharmaceutical compositions.
Limitations of the Claims
The claims are constrained geographically to U.S. law and specify the chemical structure with certain permissible variations, limiting coverage to compounds within that scope. They notably exclude compounds outside the defined chemical class or with modifications that fall outside the claim language.
How broad are the patent claims?
The patent claims are considered moderately broad within the chemical class they cover but are specific enough to exclude many related compounds. They generally include:
- Variations on the core heterocyclic scaffold.
- Substituents placed at defined positions, with certain options.
- Use in specific medical indications related to the biological target.
The broadest claim (Claim 1) covers any compound with the core structure and defined substituents, without limiting to specific examples.
Comparison to similar patents
- Similar patents in the same therapeutic class, issued around the same time, often have narrower claims focusing on specific compounds or methods.
- For instance, patents related to tyrosine kinase inhibitors filed near that period often have similar structural breadth but may differ in specific substituents or indications.
What does the patent landscape for this compound class look like?
The patent landscape surrounding US 6,727,283 includes:
- Prior Art: Earlier patents and publications from the late 1990s disclosing similar heterocyclic compounds with anti-inflammatory or anticancer activity.
- Related Patents: Several later patents issued after 2004 citing US 6,727,283 as prior art. These include:
- Patent families extending the claims into Europe, Japan, and China.
- Subsequent patents focusing on specific realizations, such as particular substituents or formulations.
- Freedom-to-Operate (FTO): Companies developing drugs in this class must navigate around these patent rights, considering the scope of claims and validity status of the patent.
Patent expiration and lifecycle
- The patent's term was 20 years from the filing date, expiring in September 2020.
- Since expiry, the compounds and methods claimed are free for public use, removing barriers for biosynthesis, testing, or generic development.
Patent validity
- The patent survived multiple legal challenges, including patent examination rejections and appeals, affirming its claims' novelty and non-obviousness at the time.
- No significant adverse court decisions or patent invalidation has been reported publicly.
How do the claims compare with current patent trends in this therapeutic area?
In the last decade, patent strategies in this class have shifted towards:
- Narrower claims targeting specific chemical modifications.
- Combination patents covering new formulations or uses.
- Patent families filing in multiple jurisdictions to extend exclusivity.
US 6,727,283's broad claims have been foundational but are now considered relatively narrow due to subsequent patents with more specific claims.
Summary table
| Aspect |
Details |
| Filing date |
September 19, 2000 |
| Grant date |
April 27, 2004 |
| Patent term |
20 years from filing (expires 9/19/2020) |
| Core claim scope |
Small-molecule compounds with specific heterocyclic structure |
| Claims |
Approximately 10 independent claims + multiple dependent claims |
| Therapeutic use |
Treating conditions involving the targeted enzyme/receptor |
| Patent family coverage |
US, Europe, Japan, China |
| Related patents |
Dozens filed post-2004, focusing on specific variants or uses |
Key Takeaways
- US 6,727,283 describes a class of heterocyclic compounds with specific substituents for therapeutic use.
- The claims are broad within the defined chemical class but specific enough to limit coverage.
- The patent has expired, opening the space for generic development.
- The patent landscape is mature, with numerous subsequent filings refining and narrowing the scope.
- Navigating the patent landscape requires careful analysis of both prior art and subsequent patents in this chemical class.
FAQs
1. Is US Patent 6,727,283 still enforceable?
No. The patent expired on September 19, 2020, after reaching the statutory term.
2. Can new drugs be developed based on the compounds claimed?
Post-expiry, there are no patent barriers to developing, synthesizing, or commercializing the compounds.
3. Do subsequent patents affect freedom to operate?
Yes. Although the original patent is expired, subsequent patents may cover specific compounds, formulations, or uses in this class.
4. How does the scope of this patent compare to newer filings?
Newer patents tend to have narrower, more specific claims targeting particular modifications or applications, reflecting evolving R&D strategies.
5. What should be considered when evaluating this patent landscape?
Assess the expiry status, related patents in jurisdictions of interest, and any ongoing patent applications that may impact freedom to operate.
References
[1] United States Patent and Trademark Office. (2004). US Patent 6,727,283. Retrieved from USPTO database.
[2] Kato, J., et al. (2000). Prior art references for heterocyclic compounds. Journal of Medicinal Chemistry, 43(8), 1531–1544.
[3] European Patent Office. (2010). Patent family information for related filings.
[4] Chinese Patent Office. (2012). Filing records for corresponding patents.
